Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection

HIV-1 entry into CD4+ T cells requires binding of the virus to CD4 followed by engagement of either the C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) coreceptor. Pharmacologic blockade or genetic inactivation of either coreceptor protects cells from infection by viruses that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2014-01, Vol.123 (1), p.61-69
Hauptverfasser: Didigu, Chuka A., Wilen, Craig B., Wang, Jianbin, Duong, Jennifer, Secreto, Anthony J., Danet-Desnoyers, Gwenn A., Riley, James L., Gregory, Phillip D., June, Carl H., Holmes, Michael C., Doms, Robert W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:HIV-1 entry into CD4+ T cells requires binding of the virus to CD4 followed by engagement of either the C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) coreceptor. Pharmacologic blockade or genetic inactivation of either coreceptor protects cells from infection by viruses that exclusively use the targeted coreceptor. We have used zinc-finger nucleases to drive the simultaneous genetic modification of both ccr5 and cxcr4 in primary human CD4+ T cells. These gene-modified cells proliferated normally and were resistant to both CCR5- and CXCR4-using HIV-1 in vitro. When introduced into a humanized mouse model of HIV-1 infection, these coreceptor negative cells engraft and traffic normally, and are protected from infection with CCR5- and CXCR4-using HIV-1 strains. These data suggest that simultaneous disruption of the HIV coreceptors may provide a useful approach for the long-term, drug-free treatment of established HIV-1 infections. •Zinc-finger nucleases simultaneously and permanently inactivate HIV coreceptors ccr5 and cxcr4 resulting in HIV-resistant CD4+ T cells.•These HIV-resistant cells may be used to achieve a functional cure for HIV in humans.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2013-08-521229